AU Patent

AU2022205157A1 — 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof

Assigned to Sage Therapeutics LLC · Expires 2022-07-28 · 4y expired

What this patent protects

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): R5 N RI O N R7 Raa R3b 21 H H 19 HOlls. 3 , 5 6 ROb R, R4a and pharmaceutically acceptable salts thereof; wherein ==, RR 2, R3 a, R3 b, R4 a, R4, R', R, and R7 are as defined herein. …

USPTO Abstract

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): R5 N RI O N R7 Raa R3b 21 H H 19 HOlls. 3 , 5 6 ROb R, R4a and pharmaceutically acceptable salts thereof; wherein ==, RR 2, R3 a, R3 b, R4 a, R4, R', R, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022205157A1
Jurisdiction
AU
Classification
—
Expires
2022-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.